This antibody can be used for grading of different neoplasms, e.g. astrocytoma. It can be of diagnostic and prognostic value.
| Inventor | Institute |
|---|---|
| David Lane | Cancer Research UK, London Research Institute: Clare Hall Laboratories |
| Cat. #: | 151148 |
|---|---|
| Tool sub type: | Primary antibody |
| Unit size: | 100 ug |
| Research Fields: | Cancer;Cell biology;Genetics |
| Application: | FACS ; IHC ; IF ; IP ; WB |
| Target: | Proliferating cell nuclear antigen, (PCNA), also known as cyclin or polymerase delta accessory protein |
| Reactivity: | Human ; Insect ; Schizosaccharomyces pombe |
| Clone: | PC10 |
| Host: | Mouse |
| Class: | Monoclonal |
| Primary citation: | Vojtesek et al. 1992. J Immunol Methods. 151(1-2):237-44. PMID: 1378473. |
| Alternate name: | Proliferating Cell Nuclear Antigen; DNA Polymerase Delta Auxiliary Protein; ATLD2 |
|---|---|
| Product description: | This antibody can be used for grading of different neoplasms, e.g. astrocytoma. It can be of diagnostic and prognostic value. |
| Conjugation: | Unconjugated |
| Isotype: | IgG2a |
| Molecular weight: | 36 kDa |
| Immunogen: | Protein A-PCNA fusion obtained from pC2T. |
| Immunogen Uniprot ID: | P04637 |
| Myeloma used: | Sp2/0-Ag14 |
| Target background: | PCNA, also known as polymerase delta auxiliary protein, is essential for DNA replication and is involved in DNA excision and mismatch repair pathways. PCNA binds to the CDK inhibitor p21, the structure-specific endonucleases Fen1 and XPG, and DNA cytosine 5-methyltransferase (MCMT). PCNA is potentially a therapeutic target in cancer therapy and a useful marker for identifying the proliferation status of tumour tissue (i.e. relevant to prognosis). |
|---|
| Format: | Liquid |
|---|---|
| Concentration: | 0.9-1.1 mg/ml |
| Storage buffer: | PBS with 0.02% azide |
| Storage conditions: | -15° C to -25° C |
| Shipping conditions: | Dry ice |
| References: |
Pacaud et al. 2014. Sci Rep. 4:4230. PMID: 24637615. The DNMT1/PCNA/UHRF1 disruption induces tumorigenesis characterized by similar genetic and epigenetic signatures. Kuang et al. 2013. World J Gastroenterol. 19(39):6637-44. PMID: 24151393. Long-term potentiation promotes proliferation/survival and neuronal differentiation of neural stem/progenitor cells. Expression and significance of Musashi-1 in gastric cancer and precancerous lesions. Cho et al. 2013. PLoS One. 8(10):e76860. PMI… |
|---|
| Cat. # | Tool Name | |||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 151016 | Anti-CyclinA [E72.1] |
Key Info
Anti-CyclinA [E72.1]
|
View Tool | |||||||||||||||||||
| 151017 | Anti-MBP [R29.6] |
Key Info
Anti-MBP [R29.6]
|
View Tool | |||||||||||||||||||
| 151022 | Anti-IL12 [1-1A4] |
Key Info
Anti-IL12 [1-1A4]
|
View Tool | |||||||||||||||||||
| 151025 | Anti-Vascular endothelium [10] |
Key Info
Anti-Vascular endothelium [10]
|
View Tool | |||||||||||||||||||
| 151031 | Anti-RuvA [RuvA 12C6] |
Key Info
Anti-RuvA [RuvA 12C6]
|
View Tool | |||||||||||||||||||
Please note we may take up to three days to respond to your enquiry.
CancerTools.org uses the contact information provided to respond to you about our research tools and service. For more information please review our privacy policy.